Hani Gabra

Royal Children's Hospital — Australia

Medicine · Health Sciences

80h-index60.5kcitations451works0.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(165), Cancer Genomics and Diagnostics(57), Cancer Mechanisms and Therapy(47), RNA modifications and cancer(30), Epigenetics and DNA Methylation(28)

Publications420 total

FINAL OVERALL SURVIVAL RESULTS FROM THE GOG281/LOGS STUDY EVALUATING TRAMETINIB VERSUS PHYSICIAN’S CHOICE STANDARD-OF-CARE THERAPY FOR RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC)
International Journal of Gynecological Cancer·2025
LBA46 DICE trial: An international multi-centre randomised phase II study to assess the efficacy of TAK228 in combination with intravenous weekly paclitaxel compared with weekly paclitaxel alone in women with advanced/recurrent epithelial ovarian or fallopian tube cancer
Annals of Oncology·2025Open Access
7826 A single tertiary centre experience of paediatric patients receiving fertility cryopreservation prior to allogeneic haematopoietic stem cell transplant (HSCT)
2025
Bioinformatic RNA-Seq Functional Profiling of the Tumor Suppressor Gene OPCML in Ovarian Cancers: The Multifunctional, Pleiotropic Impacts of Having Three Ig Domains
Current Issues in Molecular Biology·2025Open Access
Functional RNA-Seq Profiling of the Tumor Suppressor Gene OPCML in Ovarian Cancers: The Multifunctional, Pleiotropic Impacts of Having Three Ig Domains
Preprints.org·2024Open Access
Abstract 6657: Oncolytic Vaccinia Virus Carrying OPCML Tumor Suppressor is active in Epithelial Ovarian Cancer
Cancer Research·2024· 1 cited
Author Correction: The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma
Nature Communications·2023· 3 citedOpen Access
The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma
Nature Communications·2023· 51 citedOpen Access
Interview with Dr. Gabra from The OPCML Tumor Suppressor Functions as a Cell Surface Repressor–Adaptor, Negatively Regulating Receptor Tyrosine Kinases in Epithelial Ovarian Cancer
2023Open Access
Data from The OPCML Tumor Suppressor Functions as a Cell Surface Repressor–Adaptor, Negatively Regulating Receptor Tyrosine Kinases in Epithelial Ovarian Cancer
2023Open Access
Supplementary Table 2 from The OPCML Tumor Suppressor Functions as a Cell Surface Repressor–Adaptor, Negatively Regulating Receptor Tyrosine Kinases in Epithelial Ovarian Cancer
2023Open Access
Data from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023Open Access
Supplementary Figure 4 from The OPCML Tumor Suppressor Functions as a Cell Surface Repressor–Adaptor, Negatively Regulating Receptor Tyrosine Kinases in Epithelial Ovarian Cancer
2023Open Access
Supplementary Figure 2 from The OPCML Tumor Suppressor Functions as a Cell Surface Repressor–Adaptor, Negatively Regulating Receptor Tyrosine Kinases in Epithelial Ovarian Cancer
2023Open Access
Figure S3 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023Open Access
Figure S6 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023Open Access
Figure S1 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023Open Access
Data from Biomarker Assessment of HR Deficiency, Tumor <i>BRCA1/2</i> Mutations, and <i>CCNE1</i> Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy
2023Open Access
Supplementary Table 1 from The OPCML Tumor Suppressor Functions as a Cell Surface Repressor–Adaptor, Negatively Regulating Receptor Tyrosine Kinases in Epithelial Ovarian Cancer
2023Open Access
Supplementary Figure 2 from The OPCML Tumor Suppressor Functions as a Cell Surface Repressor–Adaptor, Negatively Regulating Receptor Tyrosine Kinases in Epithelial Ovarian Cancer
2023Open Access
page 1 of 21Next →

Frequent Co-authors

John F. Smyth(10), Iain A. McNeish(9), Euan A. Stronach(9), Robert Brown(7), Charlie Gourley(7), James Paul(7), Christina Fotopoulou(6), David D.L. Bowtell(5), Andrew R. Clamp(5), James D. Brenton(5), Sarah P. Blagden(5), Marcia Hall(5), Moira Stewart(5), Jonathan A. Ledermann(4), Edward Curry(4), Maria Kyrgiou(4), Rosalind Glasspool(4), Sudha Sundar(4), Adam J.W. Paige(4), Karen J. Taylor(4)